TY - JOUR
T1 - Frequent screening for asymptomatic chlamydia and gonorrhoea infections in men who have sex with men
T2 - time to re-evaluate?
AU - Williams, Eloise
AU - Williamson, Deborah A.
AU - Hocking, Jane S.
N1 - Publisher Copyright:
© 2023 Elsevier Ltd
PY - 2023/12
Y1 - 2023/12
N2 - There is increasing debate regarding the harms and benefits of frequent asymptomatic screening for Chlamydia trachomatis and Neisseria gonorrhoeae in men who have sex with men (MSM). One concern is that frequent asymptomatic screening could result in increased antimicrobial resistance in an array of sexually acquired infections and other pathogens, due to selection pressure exerted by frequent broad-spectrum antimicrobial usage within some sexual networks. Here, we outline the harms and benefits of frequent C trachomatis and N gonorrhoeae screening in MSM in high-income settings and propose that screening frequency be reduced. We describe the evidence gaps that should be further explored to better understand the implications of reducing the frequency of asymptomatic C trachomatis and N gonorrhoeae screening in MSM and the surveillance systems that should be in place to prepare for such changes.
AB - There is increasing debate regarding the harms and benefits of frequent asymptomatic screening for Chlamydia trachomatis and Neisseria gonorrhoeae in men who have sex with men (MSM). One concern is that frequent asymptomatic screening could result in increased antimicrobial resistance in an array of sexually acquired infections and other pathogens, due to selection pressure exerted by frequent broad-spectrum antimicrobial usage within some sexual networks. Here, we outline the harms and benefits of frequent C trachomatis and N gonorrhoeae screening in MSM in high-income settings and propose that screening frequency be reduced. We describe the evidence gaps that should be further explored to better understand the implications of reducing the frequency of asymptomatic C trachomatis and N gonorrhoeae screening in MSM and the surveillance systems that should be in place to prepare for such changes.
UR - http://www.scopus.com/inward/record.url?scp=85169809637&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(23)00356-0
DO - 10.1016/S1473-3099(23)00356-0
M3 - Review article
C2 - 37516129
AN - SCOPUS:85169809637
SN - 1473-3099
VL - 23
SP - e558-e566
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
IS - 12
ER -